The authors concluded that medical treatments of women with rectovaginal endometriosis were effective for pain relief. Given that the studies were limited by size, quality and were heterogeneous with regard to drug and dosage, this conclusion should be treated with caution.
To evaluate the efficacy of medical treatments for pain associated with rectovaginal endometriosis.
Searching
PubMed and EMBASE were searched for English-Language articles from January 1989 to March 2009. Search terms were reported. Bibliographies of retrieved articles and review articles, books and monographs published on endometriosis were handsearched for additional material. No attempt was made to search for unpublished material.
Study selection
Observational and randomised controlled trials (RCTs) on the effect of of medical treatments (without surgery) on pain associated with rectovaginal endometriosis (primary or recurrent lesions) were eligible for inclusion in the review. Eligible studies had a diagnosis of rectovaginal endometriosis by vaginal and rectal examination, transvaginal and/or transrectal ultrasonography and biopsy with histological confirmation. Eligible studies had pain measurements by means of visual analogue (VAS) or verbal rating scales (VRS). Studies were included if medication was provided after surgical interventions were stopped.
Included outcomes were pain (at baseline and during treatment), quality of life during treatment, satisfaction with treatment and mean lesion size (pre-and post-treatment).
Most of the included studies were prospective non-comparative patient preference studies; an RCT was included. The number of participants in a study ranged from nine to 90. Duration of treatment ranged from six to 12 months. Included interventions were: leuprolide acetate; levonorgestrel; anastrozole; ethinylestradiol plus cyproterone acetate; danazol; letrozole plus norethisterone acetate; and ethinylestradiol plus etonogestrel. Comparators varied. Interventions were delivered by intrauterine device, vaginally or orally.
Two reviewers independently selected studies for inclusion in the review.
Assessment of study quality
Two reviewers performed study quality assessment with correction or resolution of discrepancies by a third reviewer.
Data extraction
Two reviewers independently extracted data into standardised forms. Discrepancies were resolved by discussion or consultation of a third reviewer.
Methods of synthesis
Studies were synthesised narratively. Differences between studies were discussed in the text and presented in tables.
Results of the review
Seven studies (n=217) were included in the review. There were five prospective non-comparative studies (limited quality), one RCT (adequate quality) and one patient-preference cohort study (moderate quality).
Aromatase inhibitors: Administration of vaginal anastrozole 0.25mg/day for six months (n=9, non-comparative) significantly decreased pain during treatment. Administration of oral letrozole plus progestin (n=12) significantly decreased pain during treatment and improved quality of life. Neither drug influenced endometrial foci size.
